Ruboxistaurin (CAS 169939-94-0)
Alternate Names:
LY 333531 LY333531 LY-333531
CAS Number:
169939-94-0
Molecular Weight:
468.50
Molecular Formula:
C28H28N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ruboxistaurin (CAS 169939-94-0) References
- Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. | Joy, SV., et al. 2005. Ann Pharmacother. 39: 1693-9. PMID: 16160002
- The effect of ruboxistaurin on nephropathy in type 2 diabetes. | Tuttle, KR., et al. 2005. Diabetes Care. 28: 2686-90. PMID: 16249540
- The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications. | Vinik, A. 2005. Expert Opin Investig Drugs. 14: 1547-59. PMID: 16307493
- Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction. | Yeo, KP., et al. 2006. Br J Clin Pharmacol. 61: 200-10. PMID: 16433874
- Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. | Nakamura, S., et al. 2010. Exp Eye Res. 90: 137-45. PMID: 19825373
- Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways. | Al-Onazi, AS., et al. 2016. J Pharm Pharmacol. 68: 219-32. PMID: 26817709
- Ruboxistaurin Reduces Cocaine-Stimulated Increases in Extracellular Dopamine by Modifying Dopamine-Autoreceptor Activity. | Zestos, AG., et al. 2019. ACS Chem Neurosci. 10: 1960-1969. PMID: 30384585
- Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity. | Pang, C., et al. 2020. Biomed Pharmacother. 131: 110650. PMID: 32882584
- Retinal Delivery of the Protein Kinase C-β Inhibitor Ruboxistaurin Using Non-Invasive Nanoparticles of Polyamidoamine Dendrimers. | Alshammari, RA., et al. 2022. Pharmaceutics. 14: PMID: 35890338
- Determination of Ruboxistaurin analysis in rat plasma utilizing LC-MS/MS technique. | AlQuadeib, BT., et al. 2023. Saudi Pharm J. 31: 547-553. PMID: 37063445
Inhibitor of:
9230113P08Rik, BTN2A2, C6orf126, CLEC-2A, cPKC α, cPKC βI, DGK-κ, HMP19, HNRPLL, IQCD, JM4, KBTBD8, LIN-7, MARCKS, MPP7, nPKC ε, nPKC ζ, OTOGL, OTTMUSG00000010173, Pbx2, PHLDB2, PITPβ, PKC, PKC λ/Δ, PKC-d2, Pkc1, PLC γ1, PRK1, REM2, Rsk-1, Slp3, Synapsin Ia, Synapsin IIb, TMEM132B, ZFP105, ZIP, and ZNF10.Activator of:
β-glucosidase 2, CPI-17, and PKC ν.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ruboxistaurin, 25 mg | sc-507364 | 25 mg | $1080.00 |